Mechanistic Studies of HIV-exposed Seronegative Individuals
Mechanistic Studies of HIV-exposed Seronegative Individuals
批准号:
8503631
负责人:
Peter A Anton
金额:
$36.17万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2014-02-28
关键词:
Acquired Immunodeficiency SyndromeAddressAllelesAnti-Retroviral AgentsAntigen-Presenting CellsAnusAreaBehaviorBiologicalBiological FactorsCCR5 geneCD4 Positive T LymphocytesCellular ImmunityCohort StudiesDataDefensinsDeveloped CountriesDevelopmentEducational workshopEnrollmentEpidemicEquilibriumExhibitsExposure toFatigueGeneral PopulationGeneticGenetic PolymorphismGenetic StatusGenomeGenotypeHIVHIV-1HLA AntigensHealthImmuneImmune responseImmune systemIncidenceIndividualInfectionInfection preventionIntegration Host FactorsLifeLinkLymphocyte ActivationMetabolicMinorMucous MembraneNatural HistoryNatural ImmunityPathway interactionsPattern recognition receptorPersonsPharmaceutical PreparationsPharmacologic SubstancePhenotypePredispositionPrevention approachProductionPropertyRecruitment ActivityRelative (related person)ResistanceResourcesRiskSignal TransductionSingle Nucleotide PolymorphismSiteSolutionsStimulusSurfaceSurveysUnited States National Institutes of HealthVaccinationVaccine DesignViralVirusVulnerable Populationsadaptive immunitybasecohortcopingdesignhigh riskinterestmenmen&aposs grouppandemic diseaserectalresistance mechanismsuccesstheoriestransmission processviral resistance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): As detailed in the "Request For Applications" to which this proposal responds, the mechanisms of resistance of some individuals to HIV-1 infection (highly exposed seronegative, HESN) remain poorly understood. Major questions regarding this phenomenon were raised at an NIH workshop on this topic that serves as the basis for this RFA, including: 1) What is different in HESN versus those who get infected? 2) What is the immune response in HESN and is it just a marker of exposure or a correlate of protection? 3) What are the HESN host factors that help HESN resist infection? This proposal addresses these issues by exploring the overarching hypothesis that innate immune reactivity is a key determinant of CD4+ T lymphocyte activation at mucosal surfaces, and therefore a key determinant of susceptibility to HIV-1 infection of an individual. HESN may be different in terms of innate immune reactivity, which would be a key difference in the immune response of these persons compared to the general population, and not necessarily HIV-1-specific. The host factors determining this difference likely would be genetic, which will be explored by whole genome single nucleotide polymorphism examination in a complementary study. We will pursue this hypothesis by examining a unique cohort of men in the Multicenter AIDS Cohort Study who had extremely high-risk sexual exposures in the early- to mid-1980s, yet remained uninfected. The susceptibility and reactivity of their mucosal innate immune system will be assessed using HIV-1 infection and examining the effects of defined stimuli of pattern recognition receptors. We will focus on their site of sexual exposure, the rectal mucosa. Specifically, we propose: ¿ To determine innate immune signals important for HIV-1 replication in gut mucosa and quantitate the ability of gut mucosa from HESN to support HIV-1 replication ¿ To assess the innate immune responsiveness of HESN gut mucosa to different stimuli ¿ To examine the phenotypes of antigen-presenting cells in the gut mucosa of HESN
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Topical Microbicides: Targeted Intracellular Delivery
-
批准号:8810224
-
项目类别:
-
资助金额:$58.15万
-
财政年份:2014
-
负责人:Peter A Anton
-
依托单位:
Topical Microbicides: Targeted Intracellular Delivery
-
批准号:8711813
-
项目类别:
-
资助金额:$59.83万
-
财政年份:2014
-
负责人:Peter A Anton
-
依托单位:
Data management and biostatistics
-
批准号:7979343
-
项目类别:
-
资助金额:$6.27万
-
财政年份:2009
-
负责人:Peter A Anton
-
依托单位:
Exploratory human trials of rectal microbicides
-
批准号:7979345
-
项目类别:
-
资助金额:$12.2万
-
财政年份:2009
-
负责人:Peter A Anton
-
依托单位:
Administrative
-
批准号:7979338
-
项目类别:
-
资助金额:$8.07万
-
财政年份:2009
-
负责人:Peter A Anton
-
依托单位:
Regulatory compliance and human subjects safety
-
批准号:7979340
-
项目类别:
-
资助金额:$9.16万
-
财政年份:2009
-
负责人:Peter A Anton
-
依托单位:
Mucosal Immunology Core
-
批准号:7480739
-
项目类别:
-
资助金额:$6.05万
-
财政年份:2008
-
负责人:Peter A Anton
-
依托单位:
Core A - Administrative
-
批准号:7127921
-
项目类别:
-
资助金额:$5.37万
-
财政年份:2006
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:7278576
-
项目类别:
-
资助金额:$391.94万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:7107173
-
项目类别:
-
资助金额:$244.98万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
ROLE OF SITE OF IMMUNIZATION IN ELICITING MUCOSAL IMMUNITY -ALVAC HIV (VCP205
-
批准号:7205440
-
项目类别:
-
资助金额:$4.74万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:7928470
-
项目类别:
-
资助金额:$12.2万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:6935999
-
项目类别:
-
资助金额:$241.52万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:7490689
-
项目类别:
-
资助金额:$418.47万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
A NOVEL PRE-CLINICAL MUCOSAL IMMUNIZATION AGAINST HIV-1: HIV SERONEGATIVE PAR
-
批准号:7205386
-
项目类别:
-
资助金额:$0.07万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Compartment-specific topical microbicide formulations
-
批准号:7126713
-
项目类别:
-
资助金额:$153.2万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:7928468
-
项目类别:
-
资助金额:$207.12万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Microbicide Development Program (MDP)
-
批准号:6804854
-
项目类别:
-
资助金额:$242.99万
-
财政年份:2004
-
负责人:Peter A Anton
-
依托单位:
Novel Pre-Clinical Mucosal Immunization Against HIV-1:
-
批准号:7043123
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2003
-
负责人:Peter A Anton
-
依托单位:
CORE--MUCOSAL IMMUNITY
-
批准号:6646605
-
项目类别:
-
资助金额:$12.95万
-
财政年份:2002
-
负责人:Peter A Anton
-
依托单位:
海外基金